We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Treatment of Male Pattern Baldness With Botulinum Toxin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00965640
Recruitment Status : Completed
First Posted : August 25, 2009
Last Update Posted : August 25, 2009
Information provided by:
The Crown Institute

Brief Summary:
This proof of concept study seeks to demonstrate that Botulinum toxin injections are a safe and effective method for treating this form of hair loss.

Condition or disease Intervention/treatment Phase
Male Pattern Baldness Drug: Botulinum Toxin - A injections Phase 2

Study Type : Interventional  (Clinical Trial)
Primary Purpose: Screening
Official Title: A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia
Study Start Date : December 2002
Primary Completion Date : June 2004
Study Completion Date : June 2004

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Hair Growth [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Hair Loss [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male pattern baldness
  • Norwood II-VI

Exclusion Criteria:

  • Treatment with Botulinum toxins or other hair growth interventions with past year

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00965640

Canada, Ontario
Crown Institute
Pickering, Ontario, Canada, L1V 1B1
Sponsors and Collaborators
The Crown Institute
Principal Investigator: Brian Freund, MD Crown Institute

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr. B. Freund, Principal Investigator, Crown Institute
ClinicalTrials.gov Identifier: NCT00965640     History of Changes
Other Study ID Numbers: MPB-2002-01
HPB 081023
First Posted: August 25, 2009    Key Record Dates
Last Update Posted: August 25, 2009
Last Verified: August 2009

Keywords provided by The Crown Institute:
male pattern baldness
androgenetic alopecia
hair loss

Additional relevant MeSH terms:
Alopecia Areata
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical
Botulinum Toxins
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs